'FDA-Approved Compounded' and Other Phrases That Land Pharmacies in Trouble

If you market a compounded drug, the fastest way to draw regulatory attention is not your formulation, it is your wording. Calling a compounded preparation “FDA-approved,” telling patients it is the “same as” a branded product, or promoting a compounded copy of a drug you can buy off the shelf are the marketing moves that turn a routine pharmacy into an enforcement target. Compounded drugs are not FDA-approved, and saying or implying otherwise is a claim the agency reads as misleading [5]. This post walks through the specific marketing-claim triggers, the safer phrasing for each, and the real cases that show how fast a manufacturing problem becomes a marketing and reputation problem.

This is a screening and educational tool, not legal or regulatory clearance. Your own pharmacist-in-charge, supervising physician, and counsel are the final gate on every claim.

TL;DR

• Compounded drugs are not FDA-approved. Calling one “FDA-approved,” or using language that implies approval, is the single most common claim trigger. Say what is true instead: the drug is “compounded by a licensed pharmacy” [5].
• “Same as” or “equivalent to” a branded drug is a substantiation trap. A brand-equivalence claim implies you hold bioequivalence data you almost certainly do not have. The FTC requires competent and reliable evidence behind health and efficacy claims [1].
• Marketing compounded copies of commercially available drugs is legally narrow. Compounding law allows copies only under limited conditions. Promoting them broadly invites scrutiny under the FDC Act’s definition of a drug and its approval requirements [2][5].
• CGMP and sterility deficiencies become marketing problems fast. When a 503B facility is cited for insanitary conditions, the warning letter is public, and every “safe” or “high-quality” claim you ever made is now reread against it [3].
• The safer pattern is descriptive, not comparative. Describe what the preparation is and who oversees it. Skip approval language, brand comparisons, and superiority claims, and let the client’s physician sign off.

Pattern 1: Implying FDA approval

Compounded drugs do not go through FDA’s premarket approval process, and the agency is explicit that they are not FDA-approved [5]. Yet marketing copy routinely blurs this. Phrases like “FDA-approved compounded semaglutide,” “approved by the FDA,” or even softer constructions like “meets FDA standards” all imply a status the product does not have. Under Section 201(g) of the FDC Act, these preparations are drugs, and approval claims about unapproved drugs are exactly what the agency polices [2][3].

The pattern that gets pharmacies and the clinics reselling their products in trouble is borrowing legitimacy from a process the product never went through. A patient reading “FDA-approved” reasonably concludes the specific compounded vial was reviewed and cleared. It was not.

Safer phrasing describes the real chain of custody. “Compounded by a state-licensed pharmacy” is accurate. “Prepared in a registered 503B outsourcing facility” is accurate, if true. “Compounded under USP standards” can be defensible if your processes actually meet them and you are describing the standard, not implying agency endorsement. What you cannot do is attach the word “approved” or any synonym to the drug itself.

Pattern 2: Brand-equivalence and “same as” claims

The second trigger is comparative. Copy that says a compounded preparation is the “same as,” “identical to,” or “just like” a branded drug makes an equivalence claim. Equivalence between two drug products is a technical assertion that normally rests on bioequivalence data. Most compounding pharmacies do not generate that data, which means the claim is unsubstantiated the moment it is published.

The FTC’s Health Products Compliance Guidance is direct about the evidence bar: health and efficacy claims need competent and reliable scientific evidence, and the agency evaluates the claim a reasonable consumer takes away, not just the literal words [1]. “Same active ingredient” may be true and is far safer than “same as the brand,” because the second version implies the whole product, including absorption, dosing, and effect, is interchangeable. It also implies a price-for-price swap with a clinically validated product, which is precisely the takeaway the FTC scrutinizes [1][4].

Safer phrasing stays at the ingredient and oversight level. “Contains [active ingredient]” is a fact. “Compounded as an alternative for patients who [clinical reason]” frames the use without claiming equivalence. Let the prescribing physician make any clinical comparison in the chart, where it belongs, not in the marketing.

Pattern 3: Copies of commercially available drugs, and the CGMP shadow

Compounding law allows compounded copies of commercially available drugs only under narrow conditions [5]. Marketing that promotes a compounded version of a drug a patient could simply be prescribed in its approved form, especially at scale or as a routine offering, pulls the operation toward looking like unapproved manufacturing rather than patient-specific compounding [2][5]. The marketing language (“our compounded version of [branded drug]”) is often what makes the practice visible and characterizes it.

This is where manufacturing and marketing collide. Three recent cases show the reputational mechanism. RC Outsourcing, LLC, a 503B outsourcing facility, was cited by FDA in March 2026 for serious CGMP deficiencies and insanitary conditions in sterile drug production. Apollo Care, LLC, a 503B facility in Columbia, Missouri, was cited in February 2026 for serious sterility-assurance deficiencies. Boothwyn Pharmacy, LLC was cited in January 2026 for serious deficiencies in sterile compounding while distributing GLP-1 injectables. You can read these in the compounding section of the FDA/FTC Atlas, including the RC Outsourcing entry and the Boothwyn Pharmacy entry.

The point for marketers is not the manufacturing detail, it is the aftermath. Warning letters are public [3]. Once a sterility or CGMP citation is on the record, every prior “safe,” “sterile,” “pharmaceutical-grade,” or “high-quality” claim in your marketing gets reread against that public document. Patients, competitors, and plaintiffs’ attorneys all find the same page. A clean, modest claim ages well. A superlative one becomes evidence.

How to check your compounding copy

Before a compounded-drug page, ad, or intake script goes live, run it through the free Claim Checker. It screens your text for the patterns above: approval language attached to a compounded drug, “same as” or brand-equivalence phrasing, copy claims about commercially available products, and unsubstantiated safety or quality superlatives. It flags the risky phrase and suggests a descriptive rewrite.

The Claim Checker is a screening tool, not a clearance. It catches the common triggers fast so your team and your prescribing physician spend review time on the genuinely hard calls. Run new copy through the Claim Checker first, then route flagged language to your pharmacist-in-charge and counsel for the final decision. For the broader picture of what trips an enforcement letter across health verticals, see the pillar guide on marketing claims that trigger FDA warning letters.

Frequently asked questions

Can we ever say a compounded drug is FDA-approved?

No. Compounded drugs do not go through FDA’s premarket approval process and are not FDA-approved [5]. You can describe the truthful facts, that the drug is compounded by a licensed pharmacy or prepared in a registered outsourcing facility, but you cannot attach “approved” or approval-implying language to the compounded product itself. Even softer phrasings like “FDA-cleared” or “meets FDA approval standards” carry the same misleading implication and should be removed.

Is it safe to say our compounded version is the “same as” the brand-name drug?

This is risky. “Same as” is an equivalence claim that implies bioequivalence data you most likely do not have, and the FTC expects competent and reliable scientific evidence behind efficacy and comparison claims [1]. A safer construction sticks to verifiable facts, such as naming the active ingredient (“contains semaglutide”) rather than asserting the finished products are interchangeable. Any clinical comparison belongs in the physician’s discussion with the patient, not in marketing copy.

A pharmacy we work with just got a warning letter. Does that affect our marketing?

It can. Warning letters are public records [3], and once a CGMP or sterility deficiency is documented, your past quality and safety claims get reread against it by patients, competitors, and attorneys. Review any “safe,” “sterile,” or “high-quality” language tied to that supplier, confirm what you can still substantiate, and have your counsel and prescribing physician decide what stays. Modest, descriptive claims hold up far better than superlatives in this situation.

Does the Claim Checker make our copy compliant?

No. The Claim Checker is an educational screening tool that flags common high-risk phrasing and suggests safer wording. It does not clear your marketing or substitute for review. Final responsibility sits with your pharmacist-in-charge, your supervising or prescribing physician, and your legal counsel, who are the actual gate on every claim you publish.

Citations

1. Federal Trade Commission. Health Products Compliance Guidance. December 2022. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance . Accessed June 8, 2026.
2. U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act, Section 201(g) (definition of “drug”). https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act . Accessed June 8, 2026.
3. U.S. Food and Drug Administration. Warning Letters. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters . Accessed June 8, 2026.
4. Federal Trade Commission. Enforcement Authority (Section 5, deceptive or unfair acts). https://www.ftc.gov/about-ftc/mission/enforcement-authority . Accessed June 8, 2026.
5. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers . Accessed June 8, 2026.